Product image of Letrovena (Letrozole) supplied by GNH India

Letrovena

Active Ingredient:
Letrozole
Origin:
EU

Letrovena (Letrozole)

Letrozole, the active ingredient in Letrovena, is an aromatase inhibitor presented as a tablet (strength not specified) for oral use. It is employed to treat hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen‑driven tumor growth and improving disease‑free survival outcomes.

GNH India supplies Letrovena as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, pharmacies and clinical research sites worldwide, adhering to stringent quality standards, regulatory compliance and providing reliable sourcing for global therapeutic programs across multiple continents.

Manufacturer / TM Owner

Vipharm S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrovena (letrozole) acts on estrogen synthesis pathways and is indicated for several breast‑cancer treatment settings.

  • Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer: reduces risk of recurrence after surgery.
  • Neoadjuvant therapy before surgery: may shrink tumor size to facilitate breast‑conserving surgery.
  • Metastatic hormone receptor‑positive breast cancer: slows disease progression and prolongs survival.
  • Extended adjuvant therapy after initial treatment: maintains disease‑free status.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme, inhibiting its activity in peripheral tissues. This blockade prevents the conversion of androgens to estrogens, leading to markedly reduced circulating estrogen levels, which diminishes estrogen‑driven tumor proliferation in hormone‑sensitive breast cancer.

Side Effects

Common Side Effects

  • Hot flashes: transient episodes of warmth and sweating.
  • Joint and muscle pain: aching discomfort in limbs.
  • Nausea: mild to moderate upset stomach.
  • Fatigue: persistent tiredness.
  • Headache: occasional mild pain.

Serious or Rare Side Effects

  • Severe liver injury: jaundice, elevated enzymes.
  • Deep vein thrombosis or pulmonary embolism: swelling, chest pain, shortness of breath.
  • Bone fracture: increased risk due to reduced estrogen.
  • Severe allergic reaction: rash, swelling, difficulty breathing.
  • QT interval prolongation: cardiac rhythm disturbance.

Precautions & Warnings

Patients should be monitored for specific safety considerations before and during therapy.

  • Monitor bone health: assess calcium and vitamin D status regularly.
  • Assess liver function: perform periodic liver‑function tests.
  • Evaluate cardiovascular risk: watch for signs of thromboembolic events.
  • Avoid use in premenopausal women: not indicated for this population.
  • Pregnancy warning: contraindicated in pregnancy; ensure effective contraception.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Potential drug interactions may affect letrozole efficacy or safety.

Major Interactions (Avoid)

  • Concurrent estrogen replacement therapy: reduces letrozole effectiveness.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma concentrations.
  • Tamoxifen: antagonistic effect on estrogen modulation.

Moderate Interactions (Monitor Closely)

  • Warfarin: may increase INR and bleeding risk.
  • CYP2C19 inhibitors (e.g., fluconazole): can raise letrozole levels modestly.
  • SSRIs with QT‑prolonging potential: monitor cardiac rhythm.

Frequently Asked Questions

Letrovena contains letrozole, an aromatase inhibitor that is prescribed to treat hormone receptor‑positive breast cancer in postmenopausal women. It is used in adjuvant, neoadjuvant, metastatic and extended‑adjuvant treatment settings to reduce estrogen‑driven tumor growth.

Letrozole reversibly inhibits the aromatase enzyme, blocking the conversion of androgens to estrogens. This results in markedly lower circulating estrogen levels, which limits the stimulation of estrogen‑dependent breast‑cancer cells and helps control disease progression.

The dose of Letrovena is determined by the prescribing physician based on the patient’s clinical condition, treatment stage and individual factors. Only a qualified healthcare professional should set the dosage and schedule.

Letrovena is contraindicated in pregnancy because it can harm the developing fetus. Women of child‑bearing potential should use effective contraception. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while on therapy.

To order Letrovena, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrovena (letrozole) is a third‑generation aromatase inhibitor with a high potency and a favorable pharmacokinetic profile. Compared with earlier agents such as anastrozole or exemestane, letrozole often provides stronger estrogen suppression, which may translate into improved disease‑free survival in certain patient groups.

Letrovena tablets should be stored at ambient temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Do not store in a refrigerator or freezer, and keep out of reach of children.

Letrovena is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not chewed or crushed unless specifically instructed.

Serious risks include severe liver injury, deep‑vein thrombosis or pulmonary embolism, bone fractures due to decreased estrogen, severe allergic reactions, and cardiac QT‑interval prolongation. Patients should be monitored regularly for these events and report any concerning symptoms promptly.

Letrovena should not be used in premenopausal women, pregnant or breastfeeding individuals, and patients with known hypersensitivity to letrozole or any excipients. It is also contraindicated in patients with severe liver impairment or uncontrolled cardiovascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT